Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others.

Dr. Curtis Schreiber led the study at CMH’s Missouri Memory Center, which was one of only 12 clinics nationwide selected to ...

Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

Leqembi is made by Japanese pharmaceutical company Eisai and its Cambridge, Massachusetts, partner, Biogen. Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval.

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Leqembi is very effective at removing amyloid plaques (a protein that clumps between neurons) from people's brains. But it doesn't reverse cognitive decline or prevent future deterioration.

Leqembi represents an innovative approach to treating Alzheimer’s. Unlike many existing therapies that only ease symptoms, this drug aims to slow the actual progression of the disease.

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

While Leqembi offers hope to patients and their families, experts say that there are still some key unanswered questions about the drug, including about its safety and effectiveness.

But Leqembi’s rollout is expected to be slow, making it unclear when Medicare will bear the full effect of the drug that people are expected to take continually.

Leqembi is very effective at removing amyloid plaques (a protein that clumps between neurons) from people's brains. But it doesn't reverse cognitive decline or prevent future deterioration.